Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
add the l to htm for link to work
Brain tumor vaccine: Dendritic cell vaccine DCVax-L is expected to be on the market.
Biotechnology company Northwest Biotherapeutics' DCVax®-L vaccine is believed to be familiar to most brain tumor patients.
The interim trial data of the previously announced phase III clinical study. Among the patients enrolled in the clinic for more than three years, 67 cases (30%) survived more than 30 months, and 44 cases (24.2%) survived more than 36 months. The median survival time of these patients is estimated to be 46.5 to 88.2 months. At the time of analysis, 108 (32.6%) of the 331 patients who participated in the trial were still alive.
So far, the clinical trials of DCVax-L have been conducted for 12 years, which is extraordinary. The first patient was enrolled 12 years ago, and the last patient was enrolled 5 years ago. Everyone is looking forward to the final data of this therapy. We have found relevant information. It is expected that the final phase 3 trial results should be released in late June or early July. The detailed data will be announced at the relevant oncology conference in the near future. We look forward to this. With the positive data of this therapy, we also look forward to its approval as the first immunotherapy for brain tumors as soon as possible!
The authors seem to have a penchant for writing anti hit pieces against anything that makes progress where they have not, read the abstracts of their prior articles, rubbish.
Great article, thanks!
KOD Kodiak Science
50.35-2.24 (-4.26%)
At close: February 22 04:00PM EST
15.50 -34.85 (-69.22%)
Pre-Market: 7:22AM EST
Just got this as a reply to my question about AF's hit piece and the company stance,
Dave Innes <Dinnes@nwbio.com>
11:03 AM (1 minute ago)
to me
He shows up like clockwork. Very predictable. Not much else to say. It’s the nature of what he does to us and many others.
Thanks for the support.
Best
Dave Innes
Sent from my iPhone
slide at 36.3 mins is curious, then at 41.3 we see the real news we are looking for, hopefully we are going to hear soon
Looking at the digital program by track, under Central Nervous System Tumors, there is this, • Ed Session: Beyond Tumor Treatment: Survivorship in Patients With Brain Tumors. Under Developmental Therapeutics—Immunotherapy, there is this, • Ed Session: Cellular Therapies: New Targets, New Technologies • Ed Session: Immune Checkpoint Inhibitors: Extending the Benefit. But when I search for Linda Liau, nothing comes up
Kristyn Power, CFA
Program Director, Canada at Northwest Biotherapeutics
Edmonton, Alberta, Canada
Experience
Northwest Biotherapeutics
Program Director, Canada
Northwest Biotherapeutics Permanent Full-time
Dates EmployedApr 2021 – Present
Canada
Deloitte Canada
Total Duration7 yrs 5 mos
Manager
Aug 2015 – Mar 2021
5 yrs 8 mos
Edmonton, AB
• Provide advisory support to maximize value through long-term and short-term financial planning and the implementation of various strategies. Supported strategic reviews for government ministries and a municipal government.
My bad, she is interim
Janet Woodcock is Biden’s choice for head of the FDA. She has been very involved in the innovative approaches at the FDA. This is worth a read.
https://www.fda.gov/news-events/fda-voices/innovation-new-drug-approvals-2019-advances-patient-care-across-broad-range-diseases
updated: 04/19/2020
DCVax-L (and other dendritic cell vaccines)
by Stephen Western
Astrocytoma Options.com
Dendritic cells are immune cells which circulate in the blood, whose main function is to process and present antigens to T-cells, which may then target any cell bearing the antigen.
Dendritic cell based vaccine therapies require sufficient fresh tumour material from the patient receiving the vaccine, as well as the collection of dendritic cells from the patient, by leukapheresis. The dendritic cells are multiplied and co-cultured with the tumour lysate and later the DC cells, now capable of presenting tumour antigens to immune effector cells, are re-injected into the patient intra-dermally.
A personalized dendritic cell vaccine therapy called DCVax-L, developed by Northwest Biotherapeutics (based in Bethesda, Maryland, USA), is currently being tested in a phase III trial for glioblastoma, with estimated primary completion date of September 2014. This trial is recruiting at 54 study locations across the United States and one in London, UK, with an estimated enrollment of 300 patients. Patients joining this trial must have sufficient tumor material available from surgery to create the vaccine, and must undergo standard radiochemotherapy. Patients are randomized into two groups: one group receives injections of their own peripheral blood mononuclear (white blood) cells following radiochemotherapy (control arm); the other group receives the DCVax-L vaccine, in which the patient's dendritic cells pick up tumor antigens by co-culture with tissue from the patient's tumor.
In a small preliminary trial including 23 newly diagnosed and recurrent glioblastoma patients, the vaccine showed excellent results, with the 15 newly diagnosed patients having a median survival time of 35.9 months, which is roughly double the median survival time for glioblastoma patients receiving the standard radiation and TMZ protocol (1).
I wasn't aware she was affiliated with any other than Toucan Capitol, what other company are you talking about?
I agree Irish, the loss of the patents was due to lies, and Du's inability to understand the material, as well as the covington crew not catching the cropped table, and Singer not either, so we lost on so many counts!
I love the fact that each and every entry on page 12 shows settlement or active litigation, what a bunch of scumbags. I retired from process development at Pfizer and know what it takes to get a drug to market. The fact that the generics can hamstring the drug companys by litigation is and always has been disgusting to me. They should be made to wait until it is off patent and not be allowed to incur higher costs on legitimate research companies!
I agree with Jimcal22, you have been great and have done a lot! As has Hindukush, North4000, HDG, JL, so many and I am sure I am missing people, but have been here since 2012, 32000 strong, and never sold, maybe my bad, but hope is still alive. Thanks for everything the positive folks have done for this board
Thanks for being a steady force on this stock, holding since 2012 and came close a few times on bailing, but thanks to you and other steady folks, have held till generics is over. Have over 32000 and wish I had more to add now.
Now that was funny!!! Keep them coming HD! You and JL are two of my many favorites on this board, been here since 2012, never sold, just added, up to 32100 shares now, looking forward to many happy returns!!!
That was the funniest thing you have written yet!!!
You're killing us HD!
Welcome back, I hope!
Well said Tasty, I've been here since 2012, rode it all the way, not a trader so only added, never sold. This only needs another 15.00 over today and I'm retired very comfortably!!!
Congratulations, now I have a face to put with the name! I look forward to your posts, and will continue to do so!
Sorry you are leaving us, I have learned a lot from you, one of the main posters that helped me weather the 2013 adcom, still here with 32000 shares.
I remember him from Pfizer,
Budoff on now, real strong for us!
The retired police officer that just spoke was the most powerful yet!!!
Back in
The user limit for this meeting has been exceeded. Contact your meeting organizer for assistance
and we're back out
Just got reconnected
Just lost contact with the meeting, have been listening since 0800.
And that's why I always look forward to your post, clear, concise and to the point! Keep posting!
I agree!
Biogen up 33% on Alzheimer's drug revival
Please please continue to post! You are one of the very few that I look forward to seeing post as you contribute meaningful information! there are others, losing your input would be a loss!
Excellent document, very well written and concise!
Glad it was treatable and you are back, value everything you say, absolutely one of those who kept me going in the "bad times"
My condolences! I have read all the posts as I have the time, and follow yours, HDG, VuBru, Rosie, Raf, Avi, Soonam, Zuman, Louie, RetiredCEO, and others to many to list! My apologies to those I left out! I don't post often but have been here since 2012, have 33300 shares, never sold only added when I could, actually retired from Pfizer, process development. Knew of the two Pfizer execs who went to Amarin in Mystic CT when it was a small concern. I hope we all emerge from this soon smiling from ear to ear! Good luck o all, it is your tireless DD that has kept me here, I truly believe this is going to change the face of care for many. Now you can see why I don't post very often, tech and me are strangers!